---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42312069.md"
description: "$Decoy Therapeutics(DCOY.US) surged +74%, as the company announced a PIPE financing of up to $21 million, with a $3.5 million initial payment and the remainder tied to Phase 1 / 2a clinical milestones, unlocking in batches. It was pulled up to $18 in pre-market, then smashed back to around $11 during the session—with a float of 3.4 million shares, it's easy to switch between financing dilution and clinical warrants. The catalyst merely ignited the "early short" story. The nasal spray pan-coronavirus inhibitor is still more than half a year away from Phase 1, and the probability of milestone warrants receiving all the funds is not high. The short-term price seems more driven by sentiment + retail investors, and the post-market dialogue with the European drug regulator will be the key to repricing."
datetime: "2026-06-30T10:30:33.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42312069.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42312069.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42312069.md)
author: "[本职喵星人](https://longbridge.com/en/profiles/27713076.md)"
---

# $Decoy Therapeutics(DCOY.US) surged +74%, as the c…


### Related Stocks

- [DCOY.US](https://longbridge.com/en/quote/DCOY.US.md)